A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Fitusiran (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 10 Jul 2017 According to a Sanofi Genzyme media release, results were published online today and will appear in the September 7, 2017, print issue of The New England Journal of Medicine (NEJM).
- 02 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Jul 2017.
- 02 Jun 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History